Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.55 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.53 |
| ▸ | TCF7 | P36402 | 2/20 | 0.53 |
| ▸ | BCL9 | O00512 | 1/20 | 0.53 |
| ▸ | TCF4 | P15884 | 1/20 | 0.53 |
| ▸ | CLPP | Q16740 | 1/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23813467 | 1.00 | CYP3A4 (0.55) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL30343328 | 1.00 | CYP3A4 (0.55) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL23813472 | 0.94 | CYP3A4 (0.57) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL30303106 | 0.94 | CYP3A4 (0.57) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL23804491 | 0.94 | CYP3A4 (0.57) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL30343322 | 0.94 | CYP3A4 (0.55) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL23813434 | 0.94 | CYP3A4 (0.55) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL23804456 | 0.94 | CYP3A4 (0.55) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL23813438 | 0.94 | CYP3A4 (0.54) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL23913200 | 0.94 | CYP3A4 (0.54) | CYP3A4CTNNB1TCF7BCL9TCF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545683-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2026-02-10 | — | — | US | disclosed |
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-20210317123-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3+2 PHARMA, LLC | 2021-10-14 | — | — | US | disclosed |
| US-20210317123-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3+2 PHARMA, LLC | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | CREBBP, CREB1, EP300 | CYP3A4 4402/4885CTNNB1 4/4885TCF7 44/4885 |
| US-12545683-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | CREBBP, CREB1, CTNNB1 | CYP3A4 4665/4885CTNNB1 3/4885TCF7 113/4885 |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | CREBBP, CREB1, EP300 | CYP3A4 4402/4885CTNNB1 4/4885TCF7 44/4885 |
| US-20210317123-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | CREBBP, CREB1, EP300 | CYP3A4 4402/4885CTNNB1 4/4885TCF7 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.